Related Posts
- 478 A novel antagonist monoclonal antibody against human adenosine receptor 2a (A2aR) for cancer immunotherapies
Background Adenosine signaling pathway has emerged as a key metabolic pathway that regulates tumor immunity.1…
- 759 ADPORT-601 (TT-10-101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors
Background Despite significant advances in immunotherapy, novel approaches to promoting immune response and overcoming immunosuppressive…